Skip to main content
SpringerLink
Log in

The development of Sativex® — a natural cannabis-based medicine

  • Chapter
Cannabinoids as Therapeutics

Part of the book series: Milestones in Drug Therapy MDT ((MDT))

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 219.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 279.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Aldrich MR (1997) History of therapeutic cannabis. In: ML Mathre (ed.): Cannabis in Medical Practice: A Legal, Historical and Pharmacological Overview of the Therapeutic Use of Marijuana. McFarland & Co., Inc. Jefferson NC, 28640; USA, 35–55

    Google Scholar 

  2. Russo EB (2001) Hemp for headache: An in-depth historical and scientific review of cannabis in migraine treatment. J Cannabis Ther 1(2): 21–92

    Article  Google Scholar 

  3. Russo EB (2002) Cannabis treatments in obstetrics and gynaecology: A historical review. J Cannabis Ther 2(3–4): 5–35

    Article  Google Scholar 

  4. Grinspoon L, Bakalar JB (1993) History of the use of cannabis. In: Marihuana, the Forbidden Medicine. Yale University Press, New Haven, CT

    Google Scholar 

  5. The House of Lords Science and Technology Committee — Ninth Report 1998. Cannabis: the Scientific Evidence. HMG The Stationery Office, London, UK

    Google Scholar 

  6. Gaoni Y, Mechoulam R (1964) Isolation, structure, and partial synthesis of an active constituent of hashish. JAm Chem Soc 86: 1646–1647

    Article  Google Scholar 

  7. Chan PC, Boorman GA, Bridge DA, Bucher JR, Elwell MR, Goehl TJ, Haseman JK, Rao GN, Roycroft JH, Sills RC et al. (1996) 1-Trans-Delta9-Tetrahydrocannabinol (Cas No. 1972-08-3): Studies of Toxicology and Carcinogenesis In F344/N Rats And B6c3fl Mice (Gavage Studies). U.S. Department of Health And Human Services, Public Health Service, National Institutes of Health (NIH) Technical Report Series No. NTP TR 446; NIH Publication No. 97-3362 (1996), Bethesda, MD

    Google Scholar 

  8. Joy JE, Watson SJ Jr, Benson JA Jr (eds) (1999) Marijuana and Medicine — Assessing the Science Base. Division of Neuroscience and Behavioral Health, Institute of Medicine National Academy of Sciences, National Academy Press, Washington, D.C

    Google Scholar 

  9. Beaver WT, Buring J, Goldstein A, Johnson K, Jones R, Kris MG, Mooney K, Palmberg P, Phair J (1997) NIH Report on the medical uses of marijuana, 08 August 1997. From the Workshop on the Medical Utility of Marijuana (19 and 20 Feb 1997) National Institutes of Health (NIH), Bethesda, MD

    Google Scholar 

  10. AMA Medical Marijuana (1997) Council on Scientific Affairs Report 10. Medical marijuana. American Medical Association, Interim Meeting, Dallas, TX, December 1997. http://www.ama-assn.org/ama/pub/article/2036-4299.html

    Google Scholar 

  11. (1997) Therapeutic Uses of Cannabis. BMA/Harwood Academic Publishers, Amsterdam

    Google Scholar 

  12. Ashton CH (2001) Pharmacology and effects of cannabis: a brief review. Br J Psychiat 178:101–106

    Article  Google Scholar 

  13. Robson PJ (2001) Therapeutic aspects of cannabis and cannabinoids. Br J Psychiat 178: 107–115

    Article  Google Scholar 

  14. Johns A (2001) Psychiatric aspects of cannabis use. Br J Psychiat 178: 116–122

    Article  Google Scholar 

  15. Cannabis: The Scientific and Medical Evidence (11 November 1998) HM Government: House of Lords Science and Technology Select Committee Science and Technology Ninth Report (Session 1997–98). HL 151

    Google Scholar 

  16. Therapeutic Uses of Cannabis (21 March 2001) HM Government: House of Lords Science and Technology Select Committee Science and Technology Second Report (Session 2000–01). HL 50

    Google Scholar 

  17. Elphick M, Ergetova MR (2001) The neurobiology and evolution of cannabinoid signalling. Phil Trans R Soc Lond B 356(1407): 381–408

    Article  Google Scholar 

  18. Howlett AC (1984) Inhibition of neuroblastoma adenylate cyclase by cannabinoid and nantradol compounds. Life Sci 35(17): 1803–1810

    Article  PubMed  Google Scholar 

  19. Howlett AC, Fleming MR (1984) Cannabinoid inhibition of adenylate cyclase. Pharmacology of the response in neuroblastoma cell membranes. Mol Pharmacol 26(3): 532–538

    PubMed  Google Scholar 

  20. Devane WA, Dysarz FA 3rd, Johnson MR, Melvin LS, Howlett AC (1988) Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol 34(5): 605–613

    PubMed  Google Scholar 

  21. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI (1990) Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346(6284): 561–564

    Article  PubMed  Google Scholar 

  22. Munro S, Thomas KL, Abu-Shaar M (1993) Molecular characterization of a peripheral receptor for cannabinoids. Nature 365(6441): 61–65

    Article  PubMed  Google Scholar 

  23. GW Pharmaceuticals plc website www.gwpharm.com. Research and Development/Cannabis-based Medicines/Cannabinoids. http://www.gwpharm.com/research_cannabinoids.asp

    Google Scholar 

  24. Pertwee RG (1997) Pharmacology of CB1 and CB2 Receptors. Pharmacol Ther 74(2): 129–180

    Article  PubMed  Google Scholar 

  25. Devane WA, Hanuš L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, Gibson D, Mandelbaum A, Etinger A, Mechoulam R (1992) Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258(5090): 1946–1949

    PubMed  Google Scholar 

  26. Freund TF, Katona I, Piomelli D (2003) Role of endogenous cannabinoids in synaptic signalling. Physiol Rev 83(3): 1017–1066

    PubMed  Google Scholar 

  27. Hanuš L, Abu-Lafi S, Fride E, Breuer A, Vogel Z, Shalev DE, Kustanovich I, Mechoulam R (2001) 2-Arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor. Proc Natl Acad Sci USA 98(7): 3662–3665

    Article  PubMed  Google Scholar 

  28. Porter AC, Sauer JM, Knierman MD, Becker GW, Berna MJ, Bao J, Nomikos GG, Carter P, Bymaster FP, Leese AB, Felder CC (2002) Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor. J Pharmacol Exp Ther 301(3): 1020–1024

    Article  PubMed  Google Scholar 

  29. Huang SM, Bisogno T, Trevisani M, Al-Hayani A, De Petrocellis L, Fezza F, Tognetto M, Petros TJ, Krey JF, Chu CJ, Miller JD et al. (2002) An endogenous capsaicin-like substance with high potency at recombinant and native vanilloid VR1 receptors. Proc Natl Acad Sci USA 99(12):8400–8405

    Article  PubMed  Google Scholar 

  30. Millman G, Maor Y, Horowitz M, Gallily R, Hanug L, Mechoulam R (2004) Arachidonoyl-serine, an endocannabinoid-like bioactive constituent of rat brain. 2004 Symposium on the Cannabinoids, ICRS, Burlington, Vermont, ICRS, 133

    Google Scholar 

  31. McPartland J, Russo EB (2001) Cannabis and cannabis extracts: greater than the sum of their parts? J Cannabis Ther 1(3–4): 103–132

    Article  Google Scholar 

  32. Russo EB, McPartland J (2003) Cannabis is more than simply delta-9-tetrahydrocannabinol. Psychopharmacology 165: 431–432

    PubMed  Google Scholar 

  33. Mechoulam R, Ben-Zvi Z, Shani A, Zemler H, Levy S (2001) Cannabinoids and Cannabis activity. In: WDM Paton, J Crown (eds): Cannabis and its derivatives. Oxford University Press, London, 1–13

    Google Scholar 

  34. Carlini EA, Karniol IG, Renault PF, Schuster CR (1974) Effects of marihuana in laboratory animals and man. Brit J Pharmacol 50: 299–309

    Google Scholar 

  35. Fairbairn JW, Pickens JT (1981) Activity of cannabis in relation to its delta-l-trans-tetrahydro-cannabinol con tent. Brit J Pharmacol 72: 401–409

    Google Scholar 

  36. Grinspoon L, Bakalar JB (1997) Marihuana, the forbidden medicine, revised edition. Yale University Press, New Haven, CT

    Google Scholar 

  37. Browne RG, Weissman A (1981) Discriminative stimulus properties of delta-9-tetrahydrocannabinol: mechanistic studies. J Clin Pharmacol 21(8–9 Suppl): 227S–234S

    PubMed  Google Scholar 

  38. GW Pharmaceuticals plc. Clinical Study Report GWPKOOO8 (data on file)

    Google Scholar 

  39. McPartland J (2003) Neurobiological effects of cannabinoids. Lecture: American Academy of Pain Management (AAPM), 4 Sept 2003

    Google Scholar 

  40. Walton RP (1938) ((Title?)) In: Marihuana, America’s new drug problem. J.B. Lippincott Co., Philadelphia, USA, 49

    Google Scholar 

  41. Pertwee RG (2004) The pharmacology and therapeutic potential of cannabidiol In: V Di Marzo (eds): Cannabinoids. Kluwer Academic/Plenum Publishers

    Google Scholar 

  42. Whittle BA, Guy GW, Robson P (2001) Prospects for new cannabis-based prescription medicines. J Cannabis Ther 1(3–4): 183–205

    Article  Google Scholar 

  43. Whittle BA, Guy GW (2004) Development of cannabis-based medicines: risk, benefit and serendipity. In: GW Guy, PJ Robson, BA Whittle (eds): The Medicinal Uses of Cannabis and Cannabinoids. Pharmaceutical Press, London

    Google Scholar 

  44. European Medicines Evaluation Agency (EMEA). http://www.emea.eu.int/index/indexhl.htm

    Google Scholar 

  45. Food and Drug Administration (FDA) (2004) Guidance for Industry: Botanical Drug Products (June 2004) Drug Information Branch (HFD-210), Center for Drug Evaluation and Research (CDER), FDA, Rockville, MD

    Google Scholar 

  46. Potter DJ (2004) Growth and morphology of medicinal cannabis. In: GW Guy, PJ Robson, BA Whittle (eds): The Medicinal Uses of Cannabis and Cannabinoids. Pharmaceutical Press, London

    Google Scholar 

  47. Guy GW, Flint ME (2003) A single centre, placebo-controlled, four period, crossover, tolerability study assessing, pharmacodynamic effects, pharmacokinetic characteristics and cognitive profiles of a single dose of three formulations of cannabis based medicine extracts (CBMEs) (GWPD9901), plus a two period tolerability study comparing pharmacodynamic effects and pharmacokinetic characteristics of a single dose of a cannabis based medicine extract given via two administration routes (GWPD9901 EXT). J Cannabis Ther 3(3): 35–77

    Article  Google Scholar 

  48. Guy GW, Robson PJ (2003) A Phase I, Open Label, Four-Way Crossover Study to Compare the Pharmacokinetic Profiles of a Single Dose of 20 mg of a Cannabis Based Medicine Extract (CBME) Administered on 3 Different Areas of the Buccal Mucosa and to Investigate the Pharmacokinetics of CBME per Oral in Healthy Male and Female Volunteers (GWPK0112). J Cannabis Ther 3: 79–120

    Article  Google Scholar 

  49. Guy GW, Robson PJ (2003) A Phase I, Double Blind, Three-Way Crossover Study to Assess the Pharmacokinetic Profile of Cannabis Based Medicine Extract (CBME) Administered Sublingually in Variant Cannabinoid Ratios in Normal Healthy Male Volunteers (GWPK0215). J Cannabis Ther 3: 121–152

    Article  Google Scholar 

  50. Notcutt W, Price M, Miller R, Newport S, Phillips C, Simmons S, Sansom C (2004) Initial experiences with medicinal extracts of cannabis for chronic pain: results from 34 ‘N of 1’ studies. Anaesthesia 59(5): 440–452

    Article  PubMed  Google Scholar 

  51. Wade DT, Robson PJ, House H, Makela P, Aram J (2003) A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms. Clin Rehabil 17: 21–29

    Article  PubMed  Google Scholar 

  52. Brady CM, DasGupta R, Dalton C, Wiseman OJ, Berkley KJ and Fowler CJ (2004) An open-label pilot study of cannabis-based extracts for bladder dysfunction in advanced multiple sclerosis. Mult Scler 10: 425–433

    Article  PubMed  Google Scholar 

  53. GW Pharmaceuticals — Study GWN19904 — Clinical Study Report (data on file)

    Google Scholar 

  54. GW Pharmaceuticals — Study GWCRI016 — Clinical Study Report (data on file)

    Google Scholar 

  55. Rog DJ, Young CA (2003) Randomised controlled trial of Cannabis Based Medicinal Extracts in central neuropathic pain due to multiple sclerosis. Abstracts of the 19th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS, September 17–20, 2003, Milan, Italy). Mult Sclerosis 9(Suppl. 1): S1–S162

    Article  Google Scholar 

  56. Berman JS, Symonds C, Birch R (2004) Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: results of a randomized controlled trial. Pain 112: 299–306

    Article  PubMed  Google Scholar 

  57. Sharief MK (2004) Sativex® in the treatment of patients with chronic refractory pain due to MS or other defects of neurological function. Spring Scientific Meeting (2004) Association Of British Neurologists (14–16 April 2004, Church House, Westminster, London). Abstract.

    Google Scholar 

  58. Wade DT, Makela P, Robson PJ, House H, Bateman C (2004) Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo controlled study on 160 patients. Mult Scler 10: 434–441

    Article  PubMed  Google Scholar 

  59. GW Pharmaceuticals plc — Study GWMS0106 — Clinical Study Report (data on file)

    Google Scholar 

  60. GW Pharmaceuticals plc — Study GWNP0101 — Clinical Study Report (data on file)

    Google Scholar 

  61. Svendsen KB, Jensen TS, Bach FW (2004) Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial. BMJ 329: 253–260

    Article  PubMed  Google Scholar 

  62. Nicholson AN, Turner C, Stone BM, Robson PJ (2004) Effect of D-9-Tetrahydrocannabinol and Cannabidiol on Nocturnal Sleep and Early-Morning Behavior in Young Adults. J Clin Psychopharmacol 24(3): 305–313

    PubMed  Google Scholar 

  63. Wade DT, Makela P, Robson PJ, House H, Bateman C (2005) Long-term use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis. Mult Scler; submitted

    Google Scholar 

  64. GW Pharmaceuticals plc — Study GWEXT0102 — data on file

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. GW Pharmaceuticals plc, Porton Down Science Park, Salisbury, Wiltshire, SP4 OJQ, UK

    Geoffrey W. Guy & Colin G. Stott

Authors
  1. Geoffrey W. Guy
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Colin G. Stott
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Medical Faculty, Hebrew University, Ein Kerem, Jerusalem, 91010, Israel

    Raphael Mechoulam

Rights and permissions

Reprints and permissions

Copyright information

© 2005 Birkhäuser Verlag/Switzerland

About this chapter

Cite this chapter

Guy, G.W., Stott, C.G. (2005). The development of Sativex® — a natural cannabis-based medicine. In: Mechoulam, R. (eds) Cannabinoids as Therapeutics. Milestones in Drug Therapy MDT. Birkhäuser Basel. https://doi.org/10.1007/3-7643-7358-X_14

Download citation

Publish with us

Policies and ethics

Search

Navigation